Zoetis Inc. $ZTS Shares Sold by Crestwood Advisors Group LLC

Crestwood Advisors Group LLC reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 7.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 195,991 shares of the company’s stock after selling 14,674 shares during the quarter. Crestwood Advisors Group LLC’s holdings in Zoetis were worth $28,677,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ZTS. North Star Asset Management Inc. grew its holdings in Zoetis by 4.9% in the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock valued at $225,000 after purchasing an additional 67 shares during the period. Moment Partners LLC lifted its position in shares of Zoetis by 3.2% during the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after buying an additional 72 shares in the last quarter. CVA Family Office LLC grew its stake in Zoetis by 6.7% in the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after acquiring an additional 74 shares during the period. Bank of Nova Scotia Trust Co. grew its stake in Zoetis by 4.6% in the 2nd quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock valued at $264,000 after acquiring an additional 74 shares during the period. Finally, RWA Wealth Partners LLC increased its holdings in Zoetis by 2.7% in the 2nd quarter. RWA Wealth Partners LLC now owns 2,852 shares of the company’s stock worth $445,000 after acquiring an additional 76 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the topic of several research analyst reports. UBS Group set a $136.00 target price on shares of Zoetis in a research report on Thursday, January 29th. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a report on Monday, December 15th. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Morgan Stanley set a $160.00 price target on Zoetis in a research note on Thursday, December 18th. Finally, HSBC set a $140.00 price objective on Zoetis in a research note on Wednesday, December 10th. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Price Performance

ZTS stock opened at $126.64 on Tuesday. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.00. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm has a market capitalization of $53.46 billion, a PE ratio of 21.04, a price-to-earnings-growth ratio of 2.12 and a beta of 0.96. The business has a 50 day simple moving average of $124.59 and a 200-day simple moving average of $135.21.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the previous year, the company posted $1.40 earnings per share. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is presently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.